Bahama Times

Thursday, Feb 09, 2023

‘Paradigm shift’ in cancer treatment as Moderna’s vaccine shows promise

‘Paradigm shift’ in cancer treatment as Moderna’s vaccine shows promise

Preliminary results raise hope of fundamental change in cancer treatment.

The technology that saved the day during the COVID-19 pandemic is on the cusp of doing the same for cancer.

Preliminary results from Moderna's ongoing trial of a personalized mRNA cancer vaccine given alongside an immunotherapy from MSD showed a “statistically significant and clinically meaningful reduction in the risk of disease recurrence or death,” the company said Tuesday.

The positive results from the phase 2b trial that tested the vaccine's efficacy and safety paves the way for the final stage of research and then potentially a future approval for the first mRNA cancer vaccine.

Moderna became a household name during the pandemic when its mRNA vaccine became one of two vaccines of choice for many countries. But while the company was delivering hundreds of millions of COVID-19 vaccines around the world, it was also working on trials of its pipeline of different types of cancer vaccines, including one that targets specific gene mutations.

Leading the pack is the company's personalized cancer vaccine. The vaccine, which is being delivered alongside MSD’s immunotherapy Keytruda, is meant to stimulate an immune response based on a patient’s specific tumor. Keytruda then helps the patient’s immune cells to more effectively fight the cancer. The hope was that by working together, the vaccine and the immunotherapy would be able to “bring the power of the immune system to bear on the cancer and to kill it,” said Moderna’s Chief Medical Officer Paul Burton in an interview with POLITICO.

While the current trial is testing the vaccine for melanoma, Moderna is planning additional studies to test it on other cancers. Speaking before the results were released, Burton said that if the trial succeeded it would “be a new paradigm shift, [a] foundational shift that we haven't seen for at least a decade, in a new therapeutic approach for cancer.”

Those hopes appear to have been realized. Preliminary results released today of the trial of 157 melanoma patients indicate that the risk of recurrence of cancer or death was 44 percent lower in those receiving both the vaccine and Keytruda compared to those receiving the immunotherapy alone. The next step is to publish the full data set and start discussions with regulators. Moderna and MSD plan to begin the larger phase 3 trial, which will test effectiveness in more people, in 2023 and “rapidly expand to additional tumor types.”

Cancer is the next major target for mRNA jabs, with companies like Moderna and BioNTech working to prove that their jabs can both outperform existing immunotherapies delivered on their own and provide value to cash-strapped health systems.


Cancer as a chronic disease


What makes the mRNA technology unique is that it can bring together 20 to 30 antigens — substances that trigger an immune response in the body. That's something that's fundamental to the potential success of the vaccine, as it means the immune system is shown a whole range of antigens that the tumor is expressing. “I can’t imagine how you can do that with any other technology,” said Burton.

Unlike Moderna’s COVID-19 vaccine which is “off the shelf” and not tailored to each individual patient, Moderna's personalized cancer vaccine is “supremely complex,” said Burton as “it’s really making a medicine for each individual person.”

The aim? For certain patients in the earlier stage of their disease, the hope is the treatment could potentially prevent the disease from progressing. In patients with more advanced disease, the desire is to extend their life, with their cancer becoming something of a chronic disease.

“We would hope that if we can really prove this, that it will be a fundamental shift in the way that — at least for certain kinds of cancer — we treat them and the clinical benefit could really be profound,” said Burton.

The other factor is side effects. Or rather, the relative lack of them compared to, say, chemotherapy drugs. “If you can get real clinical benefit with a really manageable safety profile, I really think could be transformational," said the chief medical officer. The topline results on Tuesday indicate that the adverse events were consistent with those reported in the phase 1 trial, which found the vaccine had an acceptable safety profile.

One of the major obstacles with immunotherapies is the price. There’s concern that the same will happen with mRNA cancer vaccines. While these kinds of decisions are some way off, it’s a concern that Sam Godfrey, senior research information manager at Cancer Research U.K. (CRUK), previously expressed concern about.

“If something's costing a million pounds per treatment for a personalized vaccine, and its effectiveness isn't much better than standard chemotherapy, which doesn't cost very much, you've got that decision about, actually, is this worth investing in?” said Godfrey earlier this year.

Moderna’s Burton said he had not yet been in discussions around price. But he argued that mRNA has “huge potential” to bring value to many people around the world. “We want to bring equitable health care to people all around the world,” he said. “So we want to work with governments and with payers to do that, but I think it's premature yet to really think about price.”

Newsletter

Related Articles

Bahama Times
Close
0:00
0:00
Today's news from Britain - 9th February 2023
The five largest oil companies in the West generated combined profits of nearly $200 billion in 2022, which has led to increased calls for governments to impose tougher windfall taxes
2 earthquakes in Turkey killed over 2,300 people
Powerful Earthquake Strikes Turkey and Syria, Killing More Than 1,300 People.
Turkish photographer Ugur Gallenkus portrays two different worlds within a single image. Brilliant work
Tennessee Bill Would Imprison People for 3 Years If They 'Lie' About Rape to Get an Abortion.
Charlie Munger, calls for a ban on cryptocurrencies in the US, following China's lead
EU found a way to use frozen Russian funds
First generation unopened iPhone set to fetch more than $50,000 at auction.
WARNING GRAPHIC CONTENT - US Memphis Police murdering innocent Tyre Nichols
Almost 30% of professionals say they've tried ChatGPT at work
Interpol seeks woman who ran elaborate exam cheating scam in Singapore
What is ChatGPT?
Bill Gates is ‘very optimistic’ about the future: ‘Better to be born 20 years from now...than any time in the past’
Tesla reported record profits and record revenues for 2022
Prince Andrew and Virginia Giuffre Photo Is Fake: Ghislaine Maxwell
Opinion | Israel’s Supreme Court Claims a Veto on Democracy
Moonwalker Buzz Aldrin Gets Married On His 93rd Birthday
Who’s Threatening Israeli Democracy?
Federal Reserve Probes Goldman’s Consumer Business
China's first population drop in six decades
Microsoft is finalising plans to become the latest technology giant to reduce its workforce during a global economic slowdown
China's foreign ministry branch in Hong Kong urges British gov't to stop the biased and double standards Hong Kong report
Tesla slashes prices globally by as much as 20 percent
1.4 Million Copies Of Prince Harry's Memoir 'Spare' Sold On 1st Day In UK
After Failing To Pay Office Rent, Twitter May Sell User Names
Lisa Marie Presley, singer and daughter of Elvis, dies aged 54
FIFA president questioned by prosecutors
Britain's Sunak breaks silence and admits using private healthcare
Hype and backlash as Harry's memoir goes on sale. Unnamed royal source says prince 'kidnapped by cult of psychotherapy and Meghan'
Saudi Arabia set to overtake India as fastest-growing major economy this year 
Google and Facebook’s dominance in digital ads challenged by rapid ascent of Amazon and TikTok
FTX fraud investigators are digging deeper into Sam Bankman-Fried's inner circle – and reportedly have ex-engineer Nishad Singh in their sights
TikTok CEO Plans to Meet European Union Regulators
UK chaos: Hong Kong emigrants duped by false prospectus
France has banned the online sale of paracetamol until February, citing ongoing supply issues
Japan reportedly to give families 1 million yen per child to move out of Tokyo
Will Canada ever become a real democracy?
Hong Kong property brokerages slash payrolls in choppy market
U.S. Moves to Seize Robinhood Shares, Silvergate Accounts Tied to FTX
Effect of EU sanctions on Moscow is ‘less than zero’ – Belgian MEP
Coinbase to Pay $100 Million in Settlement With New York Regulator
FTX assets worth $3.5bn held by Bahamas securities regulator
A Republican congressman-elect is under investigation in New York after he admitted he lied about his education and work experience.
Brazilian football legend Pele, arguably the greatest player ever, has died at the age of 82.
Hong Kong to scrap almost all its Covid rules
EU calls screening of travellers from China unjustified
US imposes Covid testing for visitors from China
Ukraine President Volodymyr Zelenskyy Addresses Joint Session of Congress - FULL SPEECH
If a country is denied the right to independence by another, it is not in a union. It is in a dictatorship.
×